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Abstract 
 
Background: A third of the population are estimated to have NAFLD of 
varying severity. Serum immunoglobulins are frequently elevated in patients 
with chronic liver disease, but little is known about serum immunoglobulin 
levels in patients with NAFLD. 
Aim: To evaluate serum immunoglobulin levels (IgA, IgG and IgM) in a large 
cohort of patients with biopsy-proven NAFLD and determine if immunoglobulin 
levels are associated with clinical or histological features. 
Methods: Patients seen in a tertiary fatty liver clinic between 1999-2009 were 
included. Liver biopsies were assessed using the Kleiner score. 
Immunoglobulin levels and other blood tests were taken at time of biopsy. 
Results: 285 patients (110 simple steatosis and 175 NASH) had serum 
immunoglobulins measured within 6 months of liver biopsy. 130 (46%) 
patients had elevated (>1x upper limit of normal) serum IgA levels, 28 (10%) 
patients had elevated IgG and 22 (8%) raised IgM. Serum IgA levels were 
elevated more frequently in patients with NASH compared with subjects with 
simple steatosis (55% vs 31%, p<0.001). Overall, 55 (19%) patients had 
advanced liver fibrosis (Kleiner stage 3-4). There was a significant positive 
association between serum IgA levels and the stage of fibrosis (p<0.001). 
Serum IgA, age, platelets, AST/ALT ratio and BMI were all independently with 
advanced fibrosis following multivariate analysis. A model constructed from 
these independent predictors accurately predicted advanced fibrosis (AUROC 
0.87). 
Conclusions: The serum IgA level was frequently elevated in patients with 
NAFLD and was an independent predictor of advanced fibrosis. 
 
Key words:  
NASH; IgA; IgG; fibrosis; steatohepatitis; fatty liver; immunoglobulins; 
diabetes. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is an important manifestation of 
obesity and the metabolic syndrome (1, 2). With increasing rates of obesity, 
NAFLD has become one of the most common causes of liver dysfunction 
worldwide, affecting 20-30% of the population in developed countries (3-5). 
NAFLD is defined as fatty infiltration affecting >5% of liver tissue (in the 
absence of excessive alcohol consumption) and can range in severity from 
simple steatosis (fat without hepatocellular injury), to steatohepatatitis (NASH; 
fat with hepatocellular injury and hepatic inflammation), which can progress to 
fibrosis and cirrhosis (2, 6). The natural history of NAFLD is variable with 
simple steatosis having a good long term prognosis with low rates of liver-
related morbidity (7-10). However, approximately 30% of patients with NASH 
will progress to cirrhosis (10, 11) and be at risk of subsequent life threatening 
liver related complications such as hepatocellular carcinoma, portal 
hypertension and liver failure (12-15).  
 
It is important to identify patients with advanced fibrosis and cirrhosis to 
screen for liver-related complications. Several previous studies have identified 
clinical and laboratory factors that are associated with fibrosis in patients with 
NAFLD including: age, the presence of diabetes, raised BMI, AST/ALT ratio, 
platelet count, serum albumin and ferritin (16-18). Some of these variables are 
included in simple non-invasive scoring systems to predict fibrosis in NAFLD 
such as the FIB-4 score and the NAFLD fibrosis score (17, 19, 20). When 
used clinically these scores have excellent negative predictive ability and can 
reliably exclude advanced fibrosis (21, 22). 
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Serum immunoglobulins are tested routinely as part of the investigation of 
subjects with suspected liver disease and a polyclonal increase in serum 
immunoglobulin levels is frequently seen in patients with liver cirrhosis (23). In 
addition, characteristic patterns of elevation in serum immunoglobulins are 
observed in specific liver diseases such as autoimmune hepatitis (raised IgG), 
primary biliary cirrhosis (raised IgM) and alcoholic liver disease (raised IgA). 
These can be used clinically to aid diagnosis (24, 25). In alcoholic liver 
disease (ALD) raised serum IgA levels are associated with more advanced 
liver fibrosis (26). Deposition of IgA in the liver has also been described in 
ALD, suggesting it might have a pathogenic role (27). Previous studies have 
shown that serum IgA levels are increased in subjects with the metabolic 
syndrome and type 2 diabetes (28, 29).  
 
To date, little is known about how serum immunoglobulin levels are altered in 
patients with NAFLD. In view of the shared pathogenic mechanisms and 
similar histological appearances in NAFLD and ALD, we hypothesised that 
serum IgA will be elevated in subjects with NAFLD, and that higher levels will 
be seen in those with more advanced fibrosis. 
 
Our aim was to a evaluate serum immunoglobulin levels (IgA, IgG and IgM) in 
a large cohort of patients with biopsy-proven NAFLD of varying severity to 
determine how frequently elevated serum immunoglobulin levels occur and 
whether there are any relationships between immunoglobulin levels and 
histological or clinical features. 
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Patients and Methods 
This study included consecutive patients with biopsy-proven NAFLD who 
attended the Newcastle Hospitals fatty liver clinic between 1999 and 2009. 
Liver biopsies were performed as part of investigation of abnormal liver 
function tests or to stage disease severity in patients with ultrasound evidence 
of NAFLD. Clinical and laboratory data were collected from the time of liver 
biopsy. This was a retrospective study of prospectively collected data. 
Alternate diagnoses were excluded, including increased alcohol intake (males 
and females consuming greater than 21/14 units of alcohol per week 
[>30/20g/day ethanol] respectively were excluded), as were any individuals 
with chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune liver 
diseases, hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s 
disease and drug induced liver disease. In addition, patients in whom 
immunoglobulins were not available within 6 months of the liver biopsy were 
excluded. The study was approved by the local ethics committee. 
 
Relevant clinical details including gender, age, weight, height and average 
current and previous alcohol intake (g/day) were obtained from all patients at 
the time of liver biopsy. The body mass index (BMI) was calculated by the 
formula: weight (kg) /height (m)2. Waist circumference (in centimetres) was 
measured at the midpoint between the lower costal edge and upper iliac crest 
following a normal expiration. Patients were identified as having diabetes if 
they had been diagnosed with diabetes according to the 2004 ADA criteria or 
if they were taking an oral hypoglycaemic drug or insulin (30). Blood test 
results were taken from the time of liver biopsy or within 6 months. The 
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normal ranges for serum IgA, IgG and IgM were 0.64-2.97 g/L, 5.8-15.4 g/L 
and 0.71-2.3 g/L respectively. Immunoglobulin levels were considered 
elevated in this study if the value was >1x the upper limit of normal (ULN). 
The NAFLD fibrosis score and FIB-4 score were calculated as previously 
described (17, 19). 
 
Percutaneous liver biopsies were performed using a Menghini needle or an 
18G BioPince liver biopsy system (Medical Devices Technologies, Gainville, 
Florida, USA). Liver biopsy specimens were assessed by an experienced 
hepatopathologist (ADB). Histological scoring was performed according to the 
according to the NIH NAFLD Clinical Research Network criteria (31). NASH 
was defined as a score of 5 or more with at least 1 for ballooning 
degeneration.  
 
All statistical analyses were performed using SPSS software version 19.0 
(SPSS Inc, Chicago, USA). Continuous normally distributed variables were 
represented as mean  standard deviation (SD). Categorical variables were 
represented as percentages and non-normal variables were summarised as 
median and interquartile range (IQR). Chi squared tests were used to 
determine the distribution of categorical variables between groups. To 
compare the means of normally distributed variables between groups the 
Student’s t test was performed. To determine differences between groups for 
continuous non-normally distributed variables, medians were compared using 
the Mann-Whitney U or Kruskal-Wallis tests. 
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To identify variables independently associated with the presence or absence 
of advanced fibrosis a backward stepwise logistic regression analysis was 
conducted correcting for age, gender, BMI, presence of diabetes, gamma-
glutamyl transferase, platelets, AST/ALT ratio, serum IgA and total serum 
immunoglobulins. Significant variables from the logistic regression analysis 
were included in a model (the BAAAP score) for clinical use to predict patients 
with advanced fibrosis. The accuracy of this score was assessed by receiver 
operating characteristic (ROC) curves. The area under the ROC (AUROC) 
was used as an index to compare the accuracy of several tests. The lower 
and upper cut-off points for sensitivity and specificity for the score were 
chosen to give 95% negative predictive value (NPV) and 75% positive 
predictive value (PPV) respectively. Previously published cut-offs for the 
NAFLD fibrosis and FIB-4 score were used (17, 21). p values < 0.05 were 
considered significant. 
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Results 
Patient characteristics 
From a total of 405 patients biopsied for NAFLD between 1999 and 2009, 285 
patients had serum immunoglobulins measured within 6 months of liver 
biopsy and were included in the analysis. Eighty-one of the patients also had 
a follow up liver biopsy. The baseline demographic, clinical and biochemical 
data for all patients is summarised in Table 1. One hundred and ten patients 
(39%) had evidence of simple steatosis and 175 (61%) had evidence of 
steatohepatitis on biopsy. Patients exhibiting all 5 stages of fibrosis were 
present in the cohort (see Table 1). Fifty-five (19%) patients had advanced 
liver fibrosis (Kleiner stage 3-4) on biopsy. 
  
Overall, 130 (46%) patients had elevated serum IgA levels (>1x ULN [>2.97 
g/L]) and 2 (0.7%) patients had evidence of IgA deficiency. The serum IgG 
was elevated (>15.4 g/L) in 28 (10%) patients and the serum IgM elevated 
(>2.3 g/L) in 22 patients (8%). A graph showing the distribution of serum IgA 
levels in the patient cohort is shown in Figure 1. A comparison of the clinical 
and demographic factors between subjects with normal serum IgA levels and 
patients with raised serum IgA is shown in Table 1. 
 
Relationship between serum IgA levels and histology 
Serum IgA levels were more frequently elevated (>1x ULN) in patients with 
NASH compared with subjects with simple steatosis (55% vs 31% p<0.001) 
and the overall median serum levels of IgA were higher in patients with NASH 
versus those with simple steatosis (3.1 [2.2-4.5] vs 2.3 [1.7-3.3] g/L p<0.001).  
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There was a significant progressive increase in the proportion of patients with 
raised serum IgA levels with increasing stages of fibrosis from 31% for 
subjects with stage 0 fibrosis to 80% with stage 4 fibrosis (p<0.001, Figure 
2A). If 1.5x ULN was used as the level for an elevated serum IgA then a 
similar relationship between serum IgA and fibrosis is seen (Figure 2B). In 
addition, there was a significant positive association between serum IgA 
levels and the stage of fibrosis (p<0.001, See Figure 3A). A similar 
relationship was observed between fibrosis and serum IgA/Total 
immunoglobulin levels (p<0.001, Figure 3B).  
 
In order to determine whether the positive association between serum IgA 
levels and NASH was dependent entirely on fibrosis or whether 
steatohepatitis was independently associated, a separate analysis was 
conducted including only patients with stage 0 or 1 fibrosis (n=194). In that 
cohort significantly more patients with histological evidence of NASH had 
elevated serum IgA levels than subjects with simple steatosis (46% vs 30% 
p=0.026), suggesting that steatohepatitis is independently associated with 
raised serum IgA levels. Subjects with elevated serum IgA levels were more 
likely to have NASH than simple steatosis (74% vs 26% p<0.001).    
 
IgG, IgM and total Immunoglobulins 
Serum IgG and total immunoglobulins levels were significantly higher in 
patients with cirrhosis (stage 4) compared with subjects with stage 0-3 fibrosis 
(p<0.001 for both, Figure 4A and 4B). However, there was no significant 
relationship between serum IgG and total Immunoglobulin levels and fibrosis 
 10 
for patients with stage 0-3 fibrosis (p=0.07 and p=0.59 respectively). There 
was no relationship between IgM levels and fibrosis.   
 
Multivariate analysis of factors associated with the presence of advanced 
fibrosis 
A comparison of the clinical and laboratory factors between subjects with 
no/mild fibrosis (Kleiner stage 0-2) and patients with advanced fibrosis (stage 
3-4) is shown in Table 2. In order to determine which of these factors were 
independently associated with advanced fibrosis a logistic regression analysis 
was conducted adjusting for age, gender, BMI, presence of diabetes, gamma-
glutamyl transferase, platelets, AST/ALT ratio, serum IgA and total serum 
immunoglobulins. Age, platelets, AST/ALT ratio, BMI and serum IgA were all 
independently associated with advanced fibrosis (see Table 3). A model to 
predict the presence of advanced fibrosis in patients with NAFLD was 
constructed from the independent predictors of advanced fibrosis [-9.9+(0.078 
x age [yrs])+(-0.01 x platelets [x109])+(1.962 x AST/ALT ratio)+ (0.103 x BMI 
m/kg2) + (0.35 x serum IgA [g/L])]. This model had an AUROC of 0.87 (95%CI 
0.82-0.92)), and performed slightly better than the NAFLD fibrosis score and 
the FIB-4 score for the prediction of advanced fibrosis (Table 4). 
 
Relationship between serum immunoglobulins and diabetes 
In line with previous reports (28, 29), serum IgA levels were significantly 
higher in patients with diabetes compared to those without (3.26 [2.15-4.57] 
vs 2.45 [1.17-3.51], p<0.001). This relationship persisted when only patients 
with stage 0-1 fibrosis were considered (diabetics 2.69 [1.96-4.23] vs. non-
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diabetics 2.34 [1.70-3.26]; p=0.04), suggesting this relationship was 
independent of fibrosis. When patients with simple steatosis were considered 
separately there was a trend towards higher serum IgA levels in diabetics 
compared with non-diabetics (2.49 [1.94-4.27] vs 2.21 [1.58-3.07] p=0.07). 
There was no relationship between serum IgG levels or total Immunoglobulin 
levels and diabetes in patients with NAFLD (p=0.51 and 0.19 respectively).  
 
Serum IgA levels and fibrosis progression 
Eighty-one patients had a follow-up liver biopsy after a median of 6.4 [3.5-8.9] 
years. Of these, 29 (36%) progressed by 1 Kleiner stage of fibrosis or more. 
In 40 (49%) patients there was no change in fibrosis stage and 12 (15%) 
patients had regression of fibrosis (≥1 Kleiner stage) between the biopsies. 
Overall, 27 (33%) patients with follow up liver biopsies had a raised serum IgA 
levels at the time of the original biopsy. There was a trend towards higher 
serum IgA levels in the progressors compared with non-progressors (2.75 g/L 
[1.94-3.93] vs 2.22 [1.59-3.12] p=0.08). 
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Discussion 
 
It is accepted that serum immunoglobulin levels are frequently increased in 
patients with cirrhosis and specific elevations of serum immunoglobulins are 
seen in some liver diseases such as PBC (IgM), autoimmune hepatitis (IgG) 
and alcoholic liver disease (IgA) (23-25). In the present study, we evaluated 
serum immunoglobulin levels in a large cohort of patients with histologically 
characterised NAFLD of varying severity. The key findings of the study were 
that serum IgA levels were elevated in almost half the NAFLD cohort and 
there was a significant positive relationship between serum IgA levels and 
fibrosis. Moreover, the serum IgA level was an independent predictor of 
advanced fibrosis and was included in a model that accurately predicted 
advanced fibrosis (Kleiner Stage 3-4) in this cohort of patients with NAFLD.   
 
With increasing rates of obesity worldwide, NAFLD has become very 
common, affecting 20-30% of the population in many developed countries (6). 
It is important to identify subjects with advanced fibrosis from this large 
proportion of the population as they are at the highest risk of liver-related 
complications (32). Many studies have looked at factors associated with 
fibrosis in NAFLD and repeatedly age, AST/ALT ratio, platelet count, the 
presence of diabetes and BMI and albumin have been shown to be 
associated with advanced fibrosis (16, 17, 20-22). Some of these factors are 
included in various models to predict advanced fibrosis such as the BARD 
score, the FIB-4 score and the NAFLD fibrosis score, which can be used 
clinically to exclude or diagnose advanced fibrosis with reasonable accuracy 
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(16, 17, 20-22). Our results show that, in addition to these known factors, 
serum IgA levels were independently associated with advanced fibrosis. A 
statistical model (BAAAP score), incorporating BMI, serum IgA, age, 
AST/ALT ratio, and platelet count showed good diagnostic accuracy for 
advanced fibrosis (AUROC 0.87). However, it needs to be validated in an 
external cohort before it can be recommended for clinical use.  
 
In the present study 46% of subjects with NAFLD had an elevated IgA (>1x 
ULN), whereas 10% had an elevated IgG and 8% an elevated IgM. Previous 
studies have shown that elevation of serum IgA levels was uncommon in 
other liver diseases such as hepatitis C, PBC and autoimmune liver disease 
(25, 33). It is well known that serum IgA levels are elevated in patients with 
alcoholic liver disease (26, 27, 29), but results of the present study suggest 
that the IgA is also specifically elevated in NAFLD. Therefore, when 
investigating patients with suspected liver disease, the finding of an elevated 
IgA should prompt clinicians to consider NAFLD as a diagnosis where there is 
no history of excessive alcohol consumption.  
 
Approximately 10-30% of patients with NAFLD have NASH, which can 
progress to cirrhosis (34, 35). Currently the only effective method of 
diagnosing NASH is by liver biopsy, but this is invasive and therefore 
impractical for widespread use. In the present study we found that significantly 
more patients with an elevated serum IgA level had NASH than simple 
steatosis (74% vs 26%). Therefore, assessment of serum IgA levels along 
with other clinical factors might help clinicians determine which patients need 
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a biopsy to confirm NASH. The search for an accurate blood test to non-
invasively diagnose NASH is an active area of clinical research. 
 
Eighty one of the patients had follow up liver biopsies in the study and 
approximately a third of the patients had progression of fibrosis over a median 
follow up of 6 years. This rate of progression was similar to previous studies 
(11, 36). There was a trend to higher serum IgA levels in the patients who had 
fibrosis progression compared with the non-progressors. As we have 
demonstrated an association between higher IgA levels and fibrosis and 
steatohepatitis, it is likely that high IgA levels reflect more severe baseline 
disease that is more likely to progress. However, the number of patients with 
follow up liver biopsies was relatively small and so this association should be 
assessed in a larger cohort of patients with NAFLD.  
 
The cause of raised IgA in patients with NAFLD is unknown. As well as being 
present in serum, IgA is secreted at high concentrations on mucosal surfaces 
of protect against external pathogens (37). A major source of IgA is the gut, 
where it plays a role in the mucosal immune response against intestinal 
bacteria (37). A previous study demonstrated that the intestinal microflora was 
different in subjects with obesity compared to lean controls, and the 
alterations were abolished after diet induced weight loss (38). In addition, 
structural changes in the intestinal mucosa occur in patients with chronic liver 
disease that allows translocation of bacteria and bacterial products, such as 
LPS, to the circulation (39). Toll-like receptors recognise bacterial products 
and evoke intense inflammatory reactions that might contribute to the 
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pathogenesis of NASH (15, 40). Therefore, it is possible that Toll-like receptor 
stimulation of B cells in response to changes in bacterial microflora and 
bacterial translocation is responsible for high IgA levels seen in NAFLD. A 
potential mechanism involving TLR9 has been suggested to cause raised IgA 
levels in patients with ALD (41). Further evaluation of the underlying 
mechanism in NAFLD is warranted.  
 
Previous studies have found high serum IgA levels in subjects with type 2 
diabetes and the metabolic syndrome (28, 29). As insulin resistance is a key 
feature of NAFLD, and the majority of subjects with the metabolic syndrome 
and type 2 diabetes have steatosis (42), it is not surprising that there is a 
shared association with elevated serum IgA levels in those conditions. In the 
present study we found that higher IgA levels were seen in diabetics than 
non-diabetics after correcting for fibrosis. Diabetes is associated with a low 
grade chronic inflammatory state, with increased levels of circulating 
proinflammatory cytokines such as TNFα and IL-6 (15, 43, 44). Higher serum 
IgA levels in diabetics might therefore be a marker of higher levels of systemic 
inflammatory activity. Further studies evaluating serum cytokines and IgA 
levels in NAFLD might help elucidate the underlying mechanisms and 
determine the cause-effect relationship. 
 
In conclusion, results from the present study show that serum IgA levels were 
frequently elevated in patients with NAFLD, with higher levels in subjects with 
NASH than simple steatosis. In addition, serum IgA levels were an 
independent predictor of advanced fibrosis in patients with NAFLD. Therefore, 
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along with other clinical features and biochemical results, assessment of the 
serum IgA might help stage disease in subjects with suspected NAFLD. 
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Tables 
Table 1. Demographic, clinical and biochemical data for 285 patients with 
NAFLD, and a comparison between subjects with normal serum IgA levels 
and patients with raised IgA levels. 
Characteristic All patients 
n=285 
Normal IgA 
n=155 
Elevated IgA 
n=130 
p value** 
Age (years) 49.8 ± 12 48 ± 13 52 ± 12 0.01* 
Gender (%male) 61% 63% 60% 0.66# 
BMI (kg/m2) 34.0 ± 5.3  34.0 ± 5.3  34.0 ± 5.3  0.98* 
Diabetes 39% 32% 48% 0.006# 
Waist Circ (cm) 108 ± 13  108 ± 15 109 ± 11 0.65*  
ALT (IU/L) 80 ± 62  81 ± 56 79 ± 69 0.81* 
AST (IU/L) 53 ± 38 51 ± 33 55 ± 43 0.35* 
GGT (IU/L) 122 ± 166  119 ± 180 123 ± 147 0.83* 
ALB (g/L) 45 ± 4 45 ± 3 44 ± 5 0.004* 
Ferritin (µg/L) 199 ± 344 173 ± 140 230 ± 488 0.2* 
Platelets (x109/L) 247 ± 72 253 ± 61 239 ± 84 0.12* 
Cholesterol (mmol/L) 5.5 ± 1.3 5.6 ± 1.4 5.5 ± 1.3 0.4* 
Trigycerides (mmol/L) 2.8 ± 2 2.8 ± 2.1 2.7 ± 1.3 0.77* 
AST/ALT ratio 0.76 ± 0.32 0.71 ± 0.31 0.80 ± 0.34 0.02* 
Serum IgA (g/L) 2.75 (1.83 – 4.14)    
Serum IgG (g/L) 11.4 (9.6 – 13.5) 10.4 (9.3-12.3) 12.5 (10.4-14.3) <0.001^ 
Serum IgM (g/L) 1.03 (0.74-1.39) 1.05 (0.74-1.41) 1.01 (0.72-1.38) 0.94^ 
TotIgs (g/L) 15.6 (13-18.2) 13.9 (12.2-15.9) 18.0 (15.6-20.4) <0.001^ 
IgA/totIgs 0.18 (0.13-0.23) 0.14 (0.11-0.17) 0.24 (0.20-0.29) <0.001^ 
Fibrosis stage 
0 
1 
2 
3 
4 
 
105 (37%) 
89 (31%) 
36 (13%) 
30 (10%) 
25 (9%) 
 
72 (46%) 
50 (32%) 
18 (12%) 
10 (7%) 
5 (3%) 
 
33 (26%) 
39 (30%) 
18 (14%) 
20 (15%) 
20 (15%) 
<0.001# 
Stage 3 or 4 fibrosis 55 (19%) 15 (10%) 50 (31%) <0.001# 
Simple steatosis/ 
NASH 
110 (39%)/  
175 (61%) 
76 (49%)/ 
79 (51%) 
34 (26%)/  
96 (74%) 
<0.001# 
Mean ± SD, Median (IQR). TotIgs = IgA+IgG+IgM. ** Comparision between 
patients with normal and raised serum IgA. *Student’s t test, # Chi squared 
test, ^ Mann-Whitney U test. 
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Table 2. Clinical and biochemical characteristics of subjects with stage 0-2 
fibrosis and patients with advanced fibrosis.   
Characteristic Stage 0-2 
n=230 
Stage 3-4 
n=55 
p value 
Age (years) 48 ± 13 59 ± 9 <0.001* 
Gender (%male) 67% 38% <0.001# 
BMI (kg/m2) 33.7 ± 5.2 35.3 ± 5.4 0.04* 
Diabetes 34% 58% 0.001# 
Waist Circ (cm) 108 ± 14 112 ± 12 0.06* 
ALT (IU/L) 84 ± 66 65 ± 43 0.05* 
AST (IU/L) 51 ± 38 58 ± 35 0.18* 
GGT (IU/L) 103 ± 100 196 ± 306 0.03* 
ALB (g/L) 45 ± 3 43 ± 7 0.09* 
Ferritin 206 ± 375 170 ± 170 0.49* 
Platelets (x109/L) 258 ± 67 200 ± 78  <0.001* 
Cholesterol (mmol/L) 5.7 ± 1.3 5.0 ± 1.3 0.001* 
Trigycerides (mmol/L) 2.8 ± 2.1 2.5 ± 1.7 0.24* 
AST/ALT ratio 0.69 ± 0.26 1.02 ± 0.41 <0.001* 
IgA 2.46 (1.76-3.62) 4.15 (2.82-5.08) <0.001^ 
IgG 11.0 (9.4-13.0) 12.9 (11.2-15.3) <0.001^ 
IgM  1.0 (0.73-1.38) 1.1 (0.8-1.44) 0.2^ 
TotIgs 15.0 (12.7-17.6) 18.2 (15.3-22.3) <0.001^ 
IgA/totIgs 0.17 (0.13-0.23) 0.21 (0.17-0.28) <0.001^ 
*Student’s t test, # Chi squared test, ^ Mann-Whitney U test. 
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Table 3. Multivariate analysis of factors associated with advanced fibrosis 
(stage 3-4) compared with stage 0-2 fibrosis. 
Factor Odds Ratio 95% CI P value 
Age 1.08 1.04 - 1.13 <0.001 
Platelets 0.99 0.98 - 0.995 <0.001 
AST/ALT ratio 7.1 2.1 - 24 0.002 
BMI 1.1 1.03 – 1.19 0.004 
Serum IgA 1.4 1.17 – 1.71 <0.001 
 
 
 Table 4. Assessment of diagnostic yield of serum immunoglobulins and other 
non-invasive scores for advanced fibrosis/cirrhosis. 
Diagnosis of advanced fibrosis (stage 3-4) 
Test AUROC 95% CI Cut-off Sens Spec PPV NPV 
IgA 0.72 0.64-0.79 2.74 80% 56% 29% 93% 
NAFLD fibrosis 
score 
0.81 0.74-0.87 -1.455 
0.676 
73% 
31% 
67% 
98% 
33% 
77% 
92% 
87% 
FIB-4 score 0.85 0.80-0.90 1.30 
3.25 
80% 
24% 
74% 
99% 
40% 
84% 
94% 
86% 
BAAAP score 0.87 0.82-0.92 -1.75 
0.25 
82% 
40% 
70% 
97% 
38% 
75% 
95% 
88% 
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Table 5. Diagnostic accuracy of the BAAAP score for the diagnosis of specific 
stages of fibrosis 
Diagnostic accuracy of the BAAAP score in comparing stages of fibrosis 
Stage of fibrosis AUROC 95% CI Cut-off Sens Spec PPV NPV 
1-4  vs 0  
(63% prevalence) 
0.71 0.65-0.77 -3.0 
-1.75 
79% 
51% 
66% 
79% 
80% 
81% 
56% 
49% 
2-4 vs 0-1  
(31% prevalence) 
0.78 0.72-0.84 -1.75 
-0.5 
70% 
27% 
74% 
96% 
52% 
75% 
85% 
75% 
3-4 vs 0-2  
(19% prevalence) 
0.87 0.82-0.92 -1.75 
0.25 
82% 
40% 
70% 
97% 
38% 
75% 
95% 
88% 
4 vs 0-3  
(9% prevalence) 
0.92 0.87-0.96 -1.75 
0.25 
100% 
56% 
34% 
94% 
13% 
48% 
100% 
96% 
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Figure legends 
 
Figure 1. Distribution of serum IgA levels in the cohort of subjects with 
NAFLD. 
 
Figure 2. Relationship between serum IgA and fibrosis. A Proportion of 
patients with elevated (>1x ULN) serum IgA levels by fibrosis stage.  B 
Proportion of patients with elevated (>1.5 x ULN) serum IgA levels by fibrosis 
stage. 
 
Figure 3. Relationship between serum IgA and serum IgA/total 
immunoglubulins and fibrosis. A Relationship between serum IgA levels and 
stage of fibrosis. B Relationship between serum IgA/totalimmunoglobulin ratio 
and stage of fibrosis. 
 
Figure 4. Relationship between serum IgG andserum  total immunoglobulins 
and fibrosis. A Relationship between the serum IgG levels and fibrosis stage. 
B Relationship between the total immunoglobulin levels and fibrosis stage. 
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